Ritter Pharmac. Com (RTTR) 1.74 $RTTR Tech Coast Angels

New Post Public Reply Private Reply Replies (0) Message Board

Sep 25, 2016 at 11:17 AM

Ritter Pharmac. Com (RTTR) 1.74 $RTTR

Tech Coast Angels Selects Top 10 "Quick Pitch" Finalists
PRWeb - Tue Sep 06, 2:34AM CDT
Tech Coast Angels - San Diego announced today the top ten finalists selected from over 140 entries to compete at its popular, annual event The John G. Watson Quick Pitch competition scheduled for October 6, 2016 at Qualcomm Hall. Hosted by esteemed venture capitalist, Court Turner, the show's innovative format pits the strongest 10 finalists in a live presentation to "pitch" a company to approximately 500 attendees and a panel of judges composed of successful investors and entrepreneurs. Since its inception, Tech Coast Angels' "Quick Pitch" has put San Diego startups on the radar of local and national venture capital and angel investors, helping to launch many successful companies including EcoATM, Rock My World and Ritter Pharmaceuticals.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance
Marketwire Canada - Mon Aug 15, 7:30AM CDT
LOS ANGELES, CA--(Marketwired - Aug 15, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"

, a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Marketwire Canada - Mon Aug 08, 7:30AM CDT
LOS ANGELES, CA--(Marketwired - Aug 8, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"

, a pharmaceutical company developing novel human gut microbiome therapeutic products to treat gastrointestinal diseases, today reported financial results and a business update for the first quarter ended March 31, 2016.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund
Marketwired - Mon Dec 21, 5:15AM CST
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"

, a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has entered into a $10 million common stock purchase agreement (the "Purchase Agreement"

and a registration rights agreement with Aspire Capital Fund, LLC ("Aspire"

, a Chicago-based institutional investor.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update
BusinessWire - Tue Nov 17, 7:30AM CST
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"

, a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the third quarter ended September 30, 2015.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals elects AnnKatrin Petersen-Jappelli MD, MSC as CMO
M2 - Wed Oct 07, 3:31AM CDT
Pharmaceutical company Ritter Pharmaceuticals (NasdaqCM:RTTR) disclosed on Tuesday that it has appointed AnnKatrin Petersen-Jappelli, MD, MSC as its chief medical officer.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer
BusinessWire - Tue Oct 06, 7:30AM CDT
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (Ritter Pharmaceuticals or the Company), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the appointment of AnnKatrin Petersen-Jappelli, M.D., M.Sc. as its Chief Medical Officer.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals to Present at the 2015 Aegis Growth Conference
BusinessWire - Thu Oct 01, 7:30AM CDT
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (Ritter Pharmaceuticals or the Company), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Michael Step, Chief Executive Officer, will present a corporate overview at the 2015 Aegis Growth Conference on Thursday, October 8, 2015.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum
BusinessWire - Tue Sep 08, 3:15PM CDT
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (Ritter), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company's Chief Executive Officer, Michael Step, will participate in the 3rd Microbiome R&D Business Collaboration Forum to be held September 10-11, 2015 in San Diego, CA.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering
BusinessWire - Mon Jun 29, 3:05PM CDT
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the closing of its previously announced initial public offering of 4,000,000 shares of its common stock at a price to the public of $5.00 per share. Ritter Pharmaceuticals, Inc. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any. Gross proceeds to Ritter from the offering were $20,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses.
RTTR: 1.74 (+0.08)

Ritter Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
BusinessWire - Wed Jun 24, 8:53AM CDT
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $5.00 per share. All of the common stock is being offered by Ritter Pharmaceuticals, Inc. The gross proceeds to Ritter Pharmaceuticals, Inc. from the initial public offering are expected to be $20,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses.
RTTR: 1.74 (+0.08)

Fogo e muito bom
M2 - Fri Jun 19, 10:24AM CDT
Companies mentioned in this article: Fogo de Chao (NASDAQ: FOGO), Wingstop (NASDAQ: WING), Fitbit (NYSE: FIT), Chipotle (NYSE: CMG), Shake Shack (NYSE: SHAK), and Source Financial (OTCQX: SRCF)
FIT: 16.98 (+0.22), SHAK: 35.26 (+0.16), RTTR: 1.74 (+0.08), CMG: 413.81 (+3.65), FOGO: 11.55 (+0.13), CAFD: 14.79 (-0.42), BWLD: 155.38 (+0.28), UNVR: 21.20 (+0.32), WING: 29.66 (+0.31), MB: 18.55 (+1.05), CYAD: 21.09 (+0.31)

Ritter Pharmaceuticals elects Gerald T Proehl to board
M2 - Thu Apr 23, 5:04AM CDT
Pharmaceutical company Ritter Pharmaceuticals disclosed on Wednesday the addition of Gerald T Proehl to its board of directors.
RTTR: 1.74 (+0.08), SPHS: 2.96 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adding Fireplaces: Home Comfort or Construction Headache?

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

7th World Media Summit Spotlights Media's Future in Beijing

The Changing Landscape of Global Media An event of this magnitude doesn't just pop up every day like a stock ticker on Wall Street. This year's 7th World Media Summit in Beijing is where nearly 500 bigwigs from all corners of the media landscape are converging. It's not about trading stocks or hitting quarterly numbers—it's about shaping how stories get told in an era...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

2027 Toy of the Year Finalists Energize Play Market

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...